Nasdaq Down 50 Points; Tesla Earnings Beat Expectations
Portfolio Pulse from Lisa Levin
U.S. stocks traded mixed with the Dow Jones gaining and the NASDAQ falling. Tesla Inc reported better-than-expected earnings and sales results for its second quarter. T2 Biosystems, PainReform Ltd, and SigmaTron International shares shot up while Vir Biotechnology, Netcapital Inc, and DURECT Corporation shares dropped.
July 20, 2023 | 1:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
PainReform Ltd shares got a boost after regaining compliance with Nasdaq listing requirements.
PainReform's regained compliance with Nasdaq listing requirements could lead to a positive short-term impact on its stock price.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 100
POSITIVE IMPACT
SigmaTron International shares were up after the company reported Q4 results.
SigmaTron's Q4 results could lead to a positive short-term impact on its stock price.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 100
POSITIVE IMPACT
Tesla reported better-than-expected Q2 earnings and sales results.
Tesla's better-than-expected earnings and sales results for Q2 could lead to a positive short-term impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
T2 Biosystems shares shot up after the FDA granted Breakthrough Device designation for the company's diagnostic test.
The FDA's Breakthrough Device designation for T2 Biosystems' diagnostic test could lead to a positive short-term impact on its stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
DURECT Corporation shares fell after the company announced a $15 million registered direct offering.
DURECT's announcement of a $15 million registered direct offering could lead to a negative short-term impact on its stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
Netcapital Inc shares were down after the company announced pricing of a public offering.
Netcapital's announcement of the pricing of a public offering could lead to a negative short-term impact on its stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
Vir Biotechnology shares dropped after the company's trial did not meet primary or secondary efficacy endpoints.
The failure of Vir Biotechnology's trial to meet primary or secondary efficacy endpoints could lead to a negative short-term impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100